Results 41 to 50 of about 36,016 (212)

Human papillomavirus persistence and clearance in women living with HIV: A five‐year retrospective analysis from an Italian university center

open access: yesActa Obstetricia et Gynecologica Scandinavica, EarlyView.
In women living with HIV, HPV clearance occurred after a mean of approximately 2 years under antiretroviral therapy. Baseline positivity for the high‐risk HPV pool was associated with delayed clearance, suggesting that HPV genotype may influence viral persistence more than immunovirological status in clinically stable patients.
Annunziata Carlea   +10 more
wiley   +1 more source

Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors

open access: yesViruses, 2011
Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are associated with a high HTLV-1 load, reducing this load may treat or prevent disease.
Antonio Mastino   +6 more
doaj   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi   +6 more
wiley   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

open access: yesHepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami   +15 more
wiley   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

open access: yesHIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson   +13 more
wiley   +1 more source

Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering

open access: yesPharmaceuticals
Background: Lamivudine is widely used alone or in combination with other anti-HIV drugs in the infant to adolescent age groups of pediatric populations. Compounding of medications is frequently used for pediatric patients.
Canberk Kayalar   +5 more
doaj   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

open access: yesHIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox   +10 more
wiley   +1 more source

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

open access: yes, 2004
Adefovir dipivoxil possesses potent in vitro and in vivo antiviral activity in wild-type hepatitis B. This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in ...
Peters, Marion G   +15 more
core   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang   +15 more
wiley   +1 more source

Real-World Experience of Telbivudine and Lamivudine as Antiviral Prophylaxis for Chemotherapy-Related Hepatitis B Reactivation

open access: yesIndonesian Journal of Cancer, 2021
Background: There is currently no data regarding the efficacy of prophylactic telbivudine in hepatitis B patients undergoing chemotherapy. This study aims to describe the results of preemptive telbivudine and lamivudine to prevent chemotherapy-related ...
Lianda Siregar   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy